Drug updated on 12/11/2024
| Dosage Form | Injection (intravenous; 345 mg/2.3 mL [150 mg/mL], 1,200 mg/8 mL [150 mg/mL]) |
| Drug Class | ANGPTL3 (angiopoietin-like 3) inhibitors |
| Ongoing and Completed Studies | ClinicalTrials.gov |
Indication
- Indicated as an adjunct to other low-density lipoprotein-cholesterol (LDL-C) lowering therapies for the treatment of adult and pediatric patients, aged 5 years and older, with homozygous familial hypercholesterolemia.
Latest News
Summary
- This summary is based on the review of one systematic review/meta-analysis. [1]
- Protein-Targeted Therapies: Statins, ezetimibe, alirocumab, evolocumab, and evinacumab are highlighted for their significant lipid-lowering abilities in familial hypercholesterolemia (FH) treatment. Evinacumab is noted among these therapies, but no specific effectiveness data or comparisons are provided in the study.
- RNA-Targeted Therapies: Mipomersen, vupanorsen, inclisiran, and ARO-ANG3 target mRNA to reduce protein production, aiming to lower lipid levels similarly to protein-targeted therapies, but the study does not offer detailed efficacy metrics.
- DNA-Targeted Therapies: Approaches like adeno-associated virus or clustered regularly interspaced palindromic repeats (CRISPR)-Cas9 modifications aim to correct genetic deficiencies, potentially improving lipid levels in FH patients. However, no specific outcomes or comparisons between DNA-targeted therapies and other treatment modalities are mentioned.
- There is no safety information available in the reviewed studies.
- There is no population type or subgroup information available in the reviewed studies.
Product Monograph / Prescribing Information
| Document Title | Year | Source |
|---|---|---|
| Evkeeza (evinacumab-dgnb) Prescribing Information. | 2023 | Regeneron Pharmaceuticals, Inc., Tarrytown, NY |
Systematic Reviews / Meta-Analyses
| Document Title | Year | Source |
|---|---|---|
| The promising novel therapies for familial hypercholesterolemia | 2022 | Journal of Clinical Laboratory Analysis |
Clinical Practice Guidelines
| Document Title | Year | Source |
|---|---|---|
| 2023 Update on European Atherosclerosis Society Consensus Statement on Homozygous Familial Hypercholesterolaemia: new treatments and clinical guidance. | 2023 | European Heart Journal |
| Current Treatment Options in Homozygous Familial Hypercholesterolemia. | 2022 | Pharmaceuticals |